Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Feb 14, 2022 9:39pm
239 Views
Post# 34428529

RE:TLT updated the corporate presentation Feb 7 2022

RE:TLT updated the corporate presentation Feb 7 2022

The 90 day data seems the same as last Q report.  So probably they are waiting for more results at end of month? For next Quarterly?  

Interesting bit on NSCLC .. "Rutherrin® + X-Ray Activation leads to a 3 log kill of human NSCLC cells in-vitro"
A 3 log kill is 99.9% Tumor cell kill.  A Tumor with 10^9 cells( a Billion cells) is reduced to 10^6 ( a million cells.  Extremely effective IMO.  They can retreat as well and add immune response for extra overall efficacy .  

https://www.brainkart.com/article/The-Log-Cell-Kill-Hypothesis_28418/

DJDawg wrote:
I'm sure there are some details in there that represent updates. They include BDT aproval in later 2022 which is interesting. Suggests may not be an imminent announcement but also suggests a high degree of confidence.

https://theralase.com/wp-content/uploads/2022/02/Corporate-PPT-020722.pdf

 

<< Previous
Bullboard Posts
Next >>